The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial
Read more at globenewswire.com
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
Provided By GlobeNewswire - Last update: Nov 25, 2025
Article Mentions:
NYSEARCA:PHGE (3/13/2026, 11:25:49 AM)
6.105
-0.26 (-4.16%)
Find more stocks in the Stock Screener
